Special Issue

Production of Plant Virus-Based Vaccines and Therapeutics

Message from the Guest Editors

Since the early 1990s, plant viruses have been genetically modified to produce non-viral gene products, resulting in high yields. Shortly after the initial production of bacterial gene products, human therapeutic products and vaccines were produced at high yields and a consistent quality. The field of plant virus-produced vaccines and therapeutics has grown, with several clinical and field trials of these products. Some completed clinical trials have successfully passed through phase 3 studies. This Special Issue aims to spotlight some of the major achievements and offer insights into the future of producing therapeutics and vaccines using whole plants with genes vectored by plant viruses. Original research articles and reviews are welcome. Research areas may include the following:

- Production of vaccines utilizing plant viral vectors;
- The production of therapeutics utilizing plant viral vectors;
- Production improvements and capabilities with plant-produced products;
- Production yield improvements;
- Emergency response capabilities with plant-produced vaccines and therapeutics.

We look forward to receiving your contributions.

Guest Editors

Dr. Laurence K. Grill
Keck Graduate Institute, Claremont, CA, USA

Dr. Kelvin Phiri
Keck Graduate Institute, Claremont, CA, USA

Deadline for manuscript submissions

30 April 2026

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/212354

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI